Dengue Vaccine (Dengvaxia / DenVax)

Dengue vaccines protect against all four serotypes of dengue virus. Qdenga (TAK-003) is now approved in India for individuals with or without prior dengue infection, unlike Dengvaxia which is only for seropositive.

The Dengue Vaccine (Dengvaxia / DenVax) is recommended for 4–60 years. It falls under the Travel vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Dengue Vaccine (Dengvaxia / DenVax) has an efficacy of Qdenga: 61–84% against dengue; 90%+ against hospitalized dengue. This means it provides significant protection against Dengue fever and Severe dengue (dengue hemorrhagic fever). Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Injection site pain; headache; myalgia; asthenia. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Dengue Vaccine (Dengvaxia / DenVax) should be avoided by: Dengvaxia: Seronegative individuals (increased risk of severe dengue). Severe allergy to prior dose.. Always inform your healthcare provider of your full medical history before vaccination.

The Dengue Vaccine (Dengvaxia / DenVax) typically costs ₹3,500–₹4,500 per dose in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.